Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Purchased by Albion Financial Group UT

Albion Financial Group UT grew its holdings in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 4.3% during the first quarter, according to its most recent Form 13F filing with the SEC. The firm owned 1,395 shares of the pharmaceutical company’s stock after purchasing an additional 57 shares during the period. Albion Financial Group UT’s holdings in Vertex Pharmaceuticals were worth $583,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of VRTX. Vanguard Group Inc. grew its holdings in Vertex Pharmaceuticals by 1.4% in the 4th quarter. Vanguard Group Inc. now owns 22,282,180 shares of the pharmaceutical company’s stock worth $9,066,396,000 after buying an additional 298,824 shares in the last quarter. Capital World Investors grew its position in Vertex Pharmaceuticals by 21.3% during the fourth quarter. Capital World Investors now owns 21,805,770 shares of the pharmaceutical company’s stock valued at $8,872,586,000 after purchasing an additional 3,824,103 shares in the last quarter. Jennison Associates LLC increased its stake in Vertex Pharmaceuticals by 3.9% in the 4th quarter. Jennison Associates LLC now owns 3,944,913 shares of the pharmaceutical company’s stock valued at $1,605,146,000 after buying an additional 147,248 shares during the period. Capital Research Global Investors lifted its position in Vertex Pharmaceuticals by 5.8% in the 4th quarter. Capital Research Global Investors now owns 3,567,664 shares of the pharmaceutical company’s stock worth $1,451,647,000 after buying an additional 195,080 shares in the last quarter. Finally, Norges Bank acquired a new stake in shares of Vertex Pharmaceuticals during the 4th quarter valued at $1,237,877,000. 90.96% of the stock is currently owned by institutional investors.

Insider Activity at Vertex Pharmaceuticals

In other Vertex Pharmaceuticals news, CMO Carmen Bozic sold 2,280 shares of the stock in a transaction on Wednesday, June 12th. The shares were sold at an average price of $478.00, for a total value of $1,089,840.00. Following the completion of the sale, the chief marketing officer now owns 32,379 shares in the company, valued at $15,477,162. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. In related news, CMO Carmen Bozic sold 2,280 shares of the business’s stock in a transaction that occurred on Wednesday, June 12th. The stock was sold at an average price of $478.00, for a total transaction of $1,089,840.00. Following the transaction, the chief marketing officer now directly owns 32,379 shares of the company’s stock, valued at approximately $15,477,162. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Reshma Kewalramani sold 1,565 shares of Vertex Pharmaceuticals stock in a transaction on Friday, May 24th. The stock was sold at an average price of $457.00, for a total transaction of $715,205.00. Following the transaction, the chief executive officer now directly owns 121,374 shares of the company’s stock, valued at $55,467,918. The disclosure for this sale can be found here. Over the last three months, insiders sold 28,366 shares of company stock valued at $13,058,787. 0.20% of the stock is owned by corporate insiders.

Vertex Pharmaceuticals Stock Performance

Shares of VRTX stock opened at $470.28 on Thursday. The company has a market capitalization of $121.36 billion, a P/E ratio of 30.52, a price-to-earnings-growth ratio of 2.46 and a beta of 0.39. Vertex Pharmaceuticals Incorporated has a 52 week low of $335.82 and a 52 week high of $486.42. The company has a debt-to-equity ratio of 0.02, a quick ratio of 3.29 and a current ratio of 3.50. The company’s 50 day moving average price is $447.69 and its two-hundred day moving average price is $427.70.

Vertex Pharmaceuticals (NASDAQ:VRTX) last announced its earnings results on Monday, May 6th. The pharmaceutical company reported $4.76 earnings per share for the quarter, topping analysts’ consensus estimates of $3.66 by $1.10. Vertex Pharmaceuticals had a net margin of 39.46% and a return on equity of 23.08%. The firm had revenue of $2.69 billion during the quarter, compared to analyst estimates of $2.58 billion. During the same period in the prior year, the business earned $2.67 EPS. The company’s revenue for the quarter was up 13.3% compared to the same quarter last year. On average, analysts expect that Vertex Pharmaceuticals Incorporated will post 15.08 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of research firms have recently weighed in on VRTX. Wells Fargo & Company upped their price target on shares of Vertex Pharmaceuticals from $540.00 to $555.00 and gave the stock an “overweight” rating in a research note on Monday, June 24th. Piper Sandler boosted their price target on Vertex Pharmaceuticals from $450.00 to $456.00 and gave the company an “overweight” rating in a research note on Tuesday, May 7th. BMO Capital Markets raised their price objective on shares of Vertex Pharmaceuticals from $480.00 to $500.00 and gave the company an “outperform” rating in a research report on Friday, May 31st. Guggenheim boosted their target price on shares of Vertex Pharmaceuticals from $445.00 to $450.00 and gave the stock a “buy” rating in a research report on Thursday, April 18th. Finally, HC Wainwright restated a “buy” rating and set a $462.00 price target on shares of Vertex Pharmaceuticals in a research note on Tuesday, May 7th. Three investment analysts have rated the stock with a sell rating, six have issued a hold rating, seventeen have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $448.61.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.